ArticleScientific reports2026
Expression analysis of blood samples shows elevated 5'-tRF-His-GTG in breast cancer patients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
tRNA-derived fragments (tRFs) have emerged as promising non-invasive biomarkers for breast cancer. Understanding their diagnostic potential is essential for improving early detection and patient outcomes. This study aimed to investigate the expression level of the 5'-tRF-His-GTG in the blood of breast cancer patients and assess its potential as a diagnostic or prognostic biomarker. Candidate tRFs were identified through bioinformatic analyses using MINTbase, MODOMICS, and BBcancer, focusing on expression likelihood in biofluids and chemical modification profiles. A total of 56 blood samples, including 28 from breast cancer patients and 28 from healthy controls, were collected. Total RNA was extracted, and cDNA was synthesized via reverse transcription. Quantitative real-time PCR was performed to assess the expression level of tRF-32-XSXMSL73VL4YK. Statistical analysis was conducted using an independent t-test with a significance threshold of p < 0.05. tRF-32-XSXMSL73VL4YK, characterized by minimal chemical modifications, was selected for further investigation. It was significantly upregulated in breast cancer patients compared to healthy controls (p < 0.001). However, no significant associations were found between its expression and clinicopathological features such as age, tumor size, TNM stage, or IHC markers (p > 0.05). Our study identifies tRF-32-XSXMSL73VL4YK as a significantly upregulated 5'tRF-His-GTG in breast cancer, yet its expression shows no correlation with key clinical characteristics. While tRF-32-XSXMSL73VL4YK may not serve as a standalone diagnostic marker due to its lack of correlation with clinical features, its consistent upregulation suggests promise as a component of a multi-marker panel or as a prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.